Next Article in Journal
Kruppel-Like Factor 15 Is Critical for the Development of Left Ventricular Hypertrophy
Next Article in Special Issue
cPKCγ-Modulated Sequential Reactivation of mTOR Inhibited Autophagic Flux in Neurons Exposed to Oxygen Glucose Deprivation/Reperfusion
Previous Article in Journal
An Integrated Approach of Proteomics and Computational Genetic Modification Effectiveness Analysis to Uncover the Mechanisms of Flood Tolerance in Soybeans
Previous Article in Special Issue
The Costimulatory Pathways and T Regulatory Cells in Ischemia-Reperfusion Injury: A Strong Arm in the Inflammatory Response?
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessReview

Novel Targets for Treating Ischemia-Reperfusion Injury in the Liver

Department of Physiology and Pathophysiology, School of Basic Medical Sciences Key Laboratory of Molecular Cardiovascular Sciences of the Ministry of Education Center for Non-Coding RNA Medicine, Peking University Health Science Center, Beijing 100191, China
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(5), 1302;
Received: 2 February 2018 / Revised: 20 April 2018 / Accepted: 24 April 2018 / Published: 26 April 2018
PDF [1250 KB, uploaded 14 May 2018]


Liver ischemia-reperfusion injury (IRI) is a major complication of hemorrhagic shock, liver transplantation, and other liver surgeries. It is one of the leading causes for post-surgery hepatic dysfunction, always leading to morbidity and mortality. Several strategies, such as low-temperature reperfusion and ischemic preconditioning, are useful for ameliorating liver IRI in animal models. However, these methods are difficult to perform in clinical surgeries. It has been reported that the activation of peroxisome proliferator activated receptor gamma (PPARγ) protects the liver against IRI, but with unidentified direct target gene(s) and unclear mechanism(s). Recently, FAM3A, a direct target gene of PPARγ, had been shown to mediate PPARγ’s protective effects in liver IRI. Moreover, noncoding RNAs, including LncRNAs and miRNAs, had also been reported to play important roles in the process of hepatic IRI. This review briefly discussed the roles and mechanisms of several classes of important molecules, including PPARγ, FAM3A, miRNAs, and LncRNAs, in liver IRI. In particular, oral administration of PPARγ agonists before liver surgery or liver transplantation to activate hepatic FAM3A pathways holds great promise for attenuating human liver IRI. View Full-Text
Keywords: liver ischemia-reperfusion injury; PPARγ; FAM3A; miRNA; LncRNA liver ischemia-reperfusion injury; PPARγ; FAM3A; miRNA; LncRNA

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Yang, W.; Chen, J.; Meng, Y.; Chen, Z.; Yang, J. Novel Targets for Treating Ischemia-Reperfusion Injury in the Liver. Int. J. Mol. Sci. 2018, 19, 1302.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top